Theriva Biologics Secures Funding for Viral Therapy Innovation
Company Announcements

Theriva Biologics Secures Funding for Viral Therapy Innovation

Theriva Biologics ( (TOVX) ) has provided an update.

Theriva Biologics, Inc. has received a €2.28 million boost from the Spanish government to enhance its THERICEL project in collaboration with the Universitat Autònoma de Barcelona, aiming to revolutionize the clinical manufacture of viral therapies. The funds, structured as a €1.33 million loan and a €0.95 million grant to UAB, will propel the development of a suspension cell platform, potentially lowering manufacturing costs and improving efficiency. This investment not only underscores the innovative potential of Theriva’s therapeutic approach but also sets the stage for faster advancement in oncolytic virus development and gene therapy.

For detailed information about TOVX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTheriva Biologics Highlights Key Achievements in Q3 2024
TheFlyTheriva Biologics price target lowered to $6 from $25 at Maxim
TheFlyTheriva Biologics reports Q3 EPS ($6.81) vs. ($4.85) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App